JPWO2020117590A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020117590A5 JPWO2020117590A5 JP2021531557A JP2021531557A JPWO2020117590A5 JP WO2020117590 A5 JPWO2020117590 A5 JP WO2020117590A5 JP 2021531557 A JP2021531557 A JP 2021531557A JP 2021531557 A JP2021531557 A JP 2021531557A JP WO2020117590 A5 JPWO2020117590 A5 JP WO2020117590A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- subject
- nucleic acid
- hiv
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 238000000034 method Methods 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000036436 anti-hiv Effects 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000003472 neutralizing effect Effects 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024068841A JP2024099671A (ja) | 2018-12-04 | 2024-04-22 | Ｈｉｖワクチン免疫原 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775192P | 2018-12-04 | 2018-12-04 | |
| US62/775,192 | 2018-12-04 | ||
| PCT/US2019/063619 WO2020117590A1 (en) | 2018-12-04 | 2019-11-27 | Hiv vaccine immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068841A Division JP2024099671A (ja) | 2018-12-04 | 2024-04-22 | Ｈｉｖワクチン免疫原 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513438A JP2022513438A (ja) | 2022-02-08 |
| JPWO2020117590A5 true JPWO2020117590A5 (https=) | 2022-11-18 |
| JP2022513438A5 JP2022513438A5 (https=) | 2022-11-18 |
| JP7483234B2 JP7483234B2 (ja) | 2024-05-15 |
Family
ID=70974318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531557A Active JP7483234B2 (ja) | 2018-12-04 | 2019-11-27 | Ｈｉｖワクチン免疫原 |
| JP2024068841A Pending JP2024099671A (ja) | 2018-12-04 | 2024-04-22 | Ｈｉｖワクチン免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068841A Pending JP2024099671A (ja) | 2018-12-04 | 2024-04-22 | Ｈｉｖワクチン免疫原 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12239698B2 (https=) |
| EP (2) | EP3891170B1 (https=) |
| JP (2) | JP7483234B2 (https=) |
| KR (1) | KR20210124205A (https=) |
| CN (2) | CN113454100B (https=) |
| AU (2) | AU2019393745B2 (https=) |
| CA (1) | CA3120324A1 (https=) |
| ES (1) | ES2993834T3 (https=) |
| PL (1) | PL3891170T3 (https=) |
| WO (1) | WO2020117590A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114732898B (zh) * | 2022-04-01 | 2023-05-09 | 中国人民解放军军事科学院军事医学研究院 | 一种CpG佐剂与抗原定点共价结合方法 |
| WO2024130122A2 (en) * | 2022-12-15 | 2024-06-20 | The Wistar Institute Of Anatomy And Biology | Hiv immunogens and methods of using same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1993001831A1 (en) | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Induction of cytotoxic t-lymphocyte responses |
| US5709860A (en) | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| DE69332485T2 (de) | 1992-08-11 | 2003-11-13 | The President And Fellows Of Harvard College, Cambridge | Immunmodulierende peptide |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| AU2002336417A1 (en) | 2001-08-31 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Methods of generating human cd4+ th1 cells |
| US8673307B1 (en) | 2009-03-09 | 2014-03-18 | The Rockefeller University | HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 |
| SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
| EP2765138B1 (en) * | 2012-11-05 | 2018-01-10 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
| WO2015134982A1 (en) * | 2014-03-07 | 2015-09-11 | Cornell University | Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers |
| ES2789348T3 (es) * | 2015-03-20 | 2020-10-26 | Us Health | Anticuerpos neutralizantes para GP120 y sus usos |
| WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2017055522A1 (en) * | 2015-09-29 | 2017-04-06 | Academisch Medisch Centrum | Stabilized env proteins of hiv |
| WO2018161049A1 (en) | 2017-03-03 | 2018-09-07 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
| WO2017165674A1 (en) * | 2016-03-23 | 2017-09-28 | International Aids Vaccine Initiative | Immunogenic trimers |
| US20210009640A1 (en) * | 2018-03-02 | 2021-01-14 | Duke University | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
-
2019
- 2019-11-27 JP JP2021531557A patent/JP7483234B2/ja active Active
- 2019-11-27 CA CA3120324A patent/CA3120324A1/en active Pending
- 2019-11-27 CN CN201980090856.3A patent/CN113454100B/zh active Active
- 2019-11-27 EP EP19893005.9A patent/EP3891170B1/en active Active
- 2019-11-27 AU AU2019393745A patent/AU2019393745B2/en active Active
- 2019-11-27 CN CN202411139072.4A patent/CN119241692A/zh active Pending
- 2019-11-27 KR KR1020217020897A patent/KR20210124205A/ko not_active Ceased
- 2019-11-27 US US17/299,852 patent/US12239698B2/en active Active
- 2019-11-27 PL PL19893005.9T patent/PL3891170T3/pl unknown
- 2019-11-27 WO PCT/US2019/063619 patent/WO2020117590A1/en not_active Ceased
- 2019-11-27 ES ES19893005T patent/ES2993834T3/es active Active
- 2019-11-27 EP EP24191310.2A patent/EP4464380A3/en not_active Withdrawn
-
2024
- 2024-04-22 JP JP2024068841A patent/JP2024099671A/ja active Pending
-
2025
- 2025-01-09 US US19/014,555 patent/US20250144197A1/en active Pending
- 2025-10-02 AU AU2025242201A patent/AU2025242201A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116082521B (zh) | 痘病毒多抗原嵌合疫苗及其用途 | |
| US7504107B2 (en) | Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response | |
| JPH01279842A (ja) | Ａ型及びｂ型肝炎混合アジュバントワクチン | |
| CN110612118A (zh) | 用于引起针对hbv的免疫应答的病毒样粒子 | |
| WO2023024609A1 (zh) | 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗 | |
| US20250339511A1 (en) | Nucleic acid vaccine against monkeypox virus and use thereof | |
| JP2013538195A (ja) | Ｈｉｖ汚染の予防、ａｉｄｓを含むｈｉｖによって引き起こされる疾患及びｈｉｖに関連する疾患の予防及び治療のための医薬及び方法 | |
| CN101878037A (zh) | 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途 | |
| JPH11501310A (ja) | レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物 | |
| JP2010504759A (ja) | ライノウイルスの新規中和性免疫原（ｎｉｍｉｖ）およびワクチン応用のためのその利用 | |
| WO2020186687A1 (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| CN117603358A (zh) | 一种广谱新型冠状病毒的双特异性抗体 | |
| JP2004533991A5 (https=) | ||
| EP2138513A1 (en) | Pharmaceutical compositions of antibodies for diseases caused by viruses | |
| US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
| WO2001060156A1 (en) | Neutralizing antibody and immunomodulatory enhancing compositions | |
| JPWO2020117590A5 (https=) | ||
| CN102218139A (zh) | 一种治疗和/或预防病毒感染的药物 | |
| CN102813920A (zh) | 一种疫苗佐剂 | |
| CN114773461B (zh) | 乙型脑炎病毒抗体1d11及其应用 | |
| CN113185586B (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| JP2006500386A (ja) | ペスト菌ｆ１抗原に特異的な抗体とペスト菌ｖ抗原に特異的な抗体のうちの１又は２種の抗体を含む抗エルシニアワクチン | |
| WO2022000845A1 (zh) | 一种预防SARS-CoV-2的重组蛋白疫苗及其制备方法 | |
| WO2007107597A2 (en) | Immunogenic construct and a method for the prophylactic or therapeutic treatment of aids |